A Phase I study evaluates IAG933, a TEAD inhibitor, in patients with advanced mesothelioma or other solid tumors harboring NF2/LATS1/LATS2 alterations or YAP/TAZ fusions.
IAG933 directly disrupts the YAP/TAZ-TEAD protein-protein interaction, leading to YAP eviction from chromatin and reduced Hippo-mediated transcription.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.